Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC)

BACKGROUND: Management of Non-Small Cell Lung Cancer (NSCLC) patients with oligoprogression remains controversial. There is limited data to support the strategy of Stereotactic Ablative Radiotherapy (SABR) targeting the oligoprogressive disease in combination with ongoing systemic treatment. We aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahig, Houda, Tonneau, Marion, Blais, Normand, Wong, Philip, Filion, Edith, Campeau, Marie-Pierre, Vu, Toni, Al-Saleh, Afnan, Tehfé, Mustapha, Florescu, Marie, Roberge, David, Masucci, Laura, Richard, Corentin, Menard, Cynthia, Routy, Bertrand
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881202/
https://www.ncbi.nlm.nih.gov/pubmed/35243022
http://dx.doi.org/10.1016/j.ctro.2021.12.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8881202/
https://www.ncbi.nlm.nih.gov/pubmed/35243022
http://dx.doi.org/10.1016/j.ctro.2021.12.008

Ejemplares similares